Literature DB >> 15911321

From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.

Barun Bhhatarai1, Rajni Garg.   

Abstract

Role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones-a new class of emerging HIV-1 protease inhibitors (HIV-PI) was investigated by using comparative QSAR. These studies show that most of the data points in the individual dataset studied fall either on positive or negative side of the optimum value of ClogP. This is why, we observe either a positive or negative ClogP term in the QSAR. To observe the optimum value of ClogP for these inhibitors, a sufficient spread in the data is required. It is hoped that the results of this study would help in optimizing substituents for better binding at enzyme pockets and guide in the design of more effective HIV-PI of this class.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911321     DOI: 10.1016/j.bmc.2005.03.049

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Microsphere preparation using the untoxic solvent glycofurol.

Authors:  Daniela Allhenn; Alf Lamprecht
Journal:  Pharm Res       Date:  2010-10-29       Impact factor: 4.200

2.  Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of Tipranavir analogs for HIV protease inhibition.

Authors:  A Srinivas Reddy; Sunil Kumar; Rajni Garg
Journal:  J Mol Graph Model       Date:  2010-03-24       Impact factor: 2.518

3.  Oral LD50 toxicity modeling and prediction of per- and polyfluorinated chemicals on rat and mouse.

Authors:  Barun Bhhatarai; Paola Gramatica
Journal:  Mol Divers       Date:  2010-08-28       Impact factor: 2.943

4.  Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.

Authors:  Rajni Garg; Barun Bhhatarai
Journal:  J Comput Aided Mol Des       Date:  2008-03-27       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.